Market Closed -
Abu Dhabi Securities Exchange
06:55:00 2024-05-13 am EDT
|
5-day change
|
1st Jan Change
|
0.952
AED
|
-1.04%
|
|
-4.61%
|
+23.80%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
1,536
|
2,126
|
1,340
|
888.4
|
1,100
|
-
|
Enterprise Value (EV)
1 |
1,536
|
2,126
|
2,133
|
888.4
|
1,880
|
1,100
|
P/E ratio
|
-4.8
x
|
32.9
x
|
-46.4
x
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
0.83
x
|
0.54
x
|
0.65
x
|
0.61
x
|
EV / Revenue
|
-
|
-
|
1.32
x
|
0.54
x
|
1.11
x
|
0.61
x
|
EV / EBITDA
|
-
|
-
|
14.8
x
|
7.99
x
|
80.7
x
|
-
|
EV / FCF
|
-
|
-
|
-48.1
x
|
12.7
x
|
24.7
x
|
-
|
FCF Yield
|
-
|
-
|
-2.08%
|
7.89%
|
4.05%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,155,228
|
1,155,228
|
1,155,228
|
1,155,228
|
1,155,228
|
-
|
Reference price
2 |
1.330
|
1.840
|
1.160
|
0.7690
|
0.9520
|
0.9520
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/20/23
|
2/13/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
1,616
|
1,638
|
1,694
|
1,798
|
EBITDA
1 |
-
|
-
|
144.6
|
111.2
|
23.3
|
-
|
EBIT
1 |
-
|
-
|
12.6
|
-30.7
|
-13.3
|
-
|
Operating Margin
|
-
|
-
|
0.78%
|
-1.87%
|
-0.79%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-293.2
|
64.4
|
-29.4
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-1.82%
|
-
|
-
|
-
|
EPS
|
-0.2770
|
0.0560
|
-0.0250
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-44.4
|
70.1
|
76.1
|
-
|
FCF margin
|
-
|
-
|
-2.75%
|
4.28%
|
4.49%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
63.04%
|
326.61%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/20/23
|
2/13/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
793
|
-
|
780
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
5.487
x
|
-
|
33.48
x
|
-
|
Free Cash Flow
1 |
-
|
-
|
-44.4
|
70.1
|
76.1
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-3.14%
|
-
|
-8.3%
|
-1.02%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
63.7
|
22.1
|
30.5
|
-
|
Capex / Sales
|
-
|
-
|
3.94%
|
1.35%
|
1.8%
|
-
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/20/23
|
2/13/24
|
-
|
-
|
Last Close Price
0.952
AED Average target price
0.72
AED Spread / Average Target -24.37% Consensus |
1st Jan change
|
Capi.
|
---|
| +23.80% | 299M | | +9.85% | 72.5B | | +13.69% | 9.11B | | -12.85% | 5.07B | | +60.16% | 5.01B | | +1.60% | 3.85B | | -19.20% | 2.46B | | +18.65% | 2.44B | | +24.62% | 2.27B | | -27.46% | 2.26B |
Specialty & Advanced Pharmaceuticals
|